Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -37.94% is 27% above its 5-year average of -51.95%, around the middle of its 5-year range (-68.76%–-23.32%).
As of the fiscal period ended Tuesday, June 30, 2026. 37.08% above its 12-month average of -60.30%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -37.94%.
RETURN ON EQUITY (ROE)
-37.94%
RETURN ON EQUITY (ROE) AVG TTM
-60.30%
RETURN ON EQUITY (ROE) AVG 3Y
-62.54%
RETURN ON EQUITY (ROE) AVG 5Y
-51.95%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+37.08%
CURRENT VS 3Y AVG
+39.34%
CURRENT VS 5Y AVG
+26.97%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.33%
median of 509 covered companies
CURRENT VS SECTOR MEDIAN
+3.53%
vs the sector median at left
Allogene Therapeutics, Inc.
Market Cap
$498.75M
Return on Equity (ROE)
-37.94%
TTM Avg
-60.30%
3Y Avg
-62.54%
5Y Avg
-51.95%
Market Cap
$507.55M
Return on Equity (ROE)
-13.64%
TTM Avg
-19.13%
3Y Avg
-73.22%
5Y Avg
-63.52%
Market Cap
$513.25M
Return on Equity (ROE)
-27.20%
TTM Avg
-44.25%
3Y Avg
-32.03%
5Y Avg
-24.61%
Market Cap
$516.46M
Return on Equity (ROE)
-19.35%
TTM Avg
-58.07%
3Y Avg
-51.86%
5Y Avg
-46.32%
Market Cap
$521.76M
Return on Equity (ROE)
-17.44%
TTM Avg
-97.25%
3Y Avg
-87.77%
5Y Avg
-77.06%
Market Cap
$473.57M
Return on Equity (ROE)
N/A
TTM Avg
-344.79%
3Y Avg
-198.42%
5Y Avg
-104.57%
Market Cap
$473.36M
Return on Equity (ROE)
-8.21%
TTM Avg
-32.76%
3Y Avg
-79.80%
5Y Avg
-71.61%
Market Cap
$471.65M
Return on Equity (ROE)
1.65%
TTM Avg
-27.02%
3Y Avg
-39.92%
5Y Avg
-33.78%
Market Cap
$471.20M
Return on Equity (ROE)
-24.02%
TTM Avg
-22.16%
3Y Avg
-34.88%
5Y Avg
-37.32%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | $498.75M | -37.94% | -60.30% | -62.54% | -51.95% |
| Monopar Therapeutics Inc. (MNPR)vs › | $507.55M | -13.64% | -19.13% | -73.22% | -63.52% |
| 908 Devices Inc. (MASS)vs › | $513.25M | -27.20% | -44.25% | -32.03% | -24.61% |
| Altimmune, Inc. (ALT)vs › | $516.46M | -19.35% | -58.07% | -51.86% | -46.32% |
| Immix Biopharma, Inc. (IMMX)vs › | $521.76M | -17.44% | -97.25% | -87.77% | -77.06% |
| Evolus, Inc. (EOLS)vs › | $473.57M | N/A | -344.79% | -198.42% | -104.57% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $473.36M | -8.21% | -32.76% | -79.80% | -71.61% |
| Arvinas, Inc. (ARVN)vs › | $471.65M | 1.65% | -27.02% | -39.92% | -33.78% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $471.20M | -24.02% | -22.16% | -34.88% | -37.32% |
| Crescent Biopharma, Inc. (CBIO)vs › | $531.34M | -99.83% | 118.83% | 8.21% | -14.12% |
ROE
-37.9%
ROA
-30.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -37.94% |
| 2026-03-31 | -62.31% |
| 2025-12-31 | -65.25% |
| 2025-09-30 | -67.24% |
| 2025-06-30 | -68.76% |
| 2025-03-31 | -65.47% |
| 2024-12-31 | -61.01% |
| 2024-09-30 | -61.87% |
| 2024-06-30 | -54.93% |
| 2024-03-31 | -64.11% |
| 2023-12-31 | -64.57% |
| 2023-09-30 | -57.68% |
| 2023-06-30 | -57.34% |
| 2023-03-31 | -59.56% |
| 2022-12-31 | -49.88% |
| 2022-09-30 | -42.25% |
| 2022-06-30 | -38.37% |
| 2022-03-31 | -35.53% |
| 2021-12-31 | -27.78% |
| 2021-09-30 | -25.85% |
| 2021-06-30 | -23.32% |
| 2021-03-31 | -21.38% |
| 2020-12-31 | -23.18% |
| 2020-09-30 | -21.69% |
| 2020-06-30 | -19.53% |
| 2020-03-31 | -34.21% |
| 2019-12-31 | -29.35% |
| 2019-09-30 | -24.86% |
| 2019-06-30 | -22.40% |
| 2019-03-31 | -35.30% |
| 2018-12-31 | -30.08% |
